Abstract
The aetiology of suicide is complex and still not completely understood. The present communication, which consists of two parts, aims to shed some light on the role of amino acidergic neurotransmission in suicide. In the first part we provide an overview of the literature showing that with the exception of certain gamma-aminobutyric acid transporters, virtually all components of the glutamate-glutamine- gamma-aminobutyric acid cycle are, in some way or other, abnormal in suicide victims, which indicates a prominent involvement of the glutamatergic and gammaaminobutyric acidergic neurotransmitter systems in suicidal behaviour. In the second part we present own immunohistochemical findings showing that densities of glutamine synthetase expressing glial cells in the mediodorsal thalamus as well as in the dorsolateral prefrontal and orbitofrontal cortex of schizophrenic suicide completers are significantly elevated compared with controls and non-suicide individuals with schizophrenia, thus calling into question the belief that cerebral glutamine synthetase deficit is indicative of suicidal behaviour.
Keywords: Gamma-aminobutyric acid, glutamate, glutamine, glutamine synthetase, human brain, immunohistochemistry, suicide.
CNS & Neurological Disorders - Drug Targets
Title:Disruption of Glutamate-Glutamine-GABA Cycle Significantly Impacts on Suicidal Behaviour: Survey of the Literature and Own Findings on Glutamine Synthetase.
Volume: 12 Issue: 7
Author(s): Hans-Gert Bernstein, Anne Tausch, Rebecca Wagner, Johann Steiner, Patrick Seeleke, Martin Walter, Henrik Dobrowolny and Bernhard Bogerts
Affiliation:
Keywords: Gamma-aminobutyric acid, glutamate, glutamine, glutamine synthetase, human brain, immunohistochemistry, suicide.
Abstract: The aetiology of suicide is complex and still not completely understood. The present communication, which consists of two parts, aims to shed some light on the role of amino acidergic neurotransmission in suicide. In the first part we provide an overview of the literature showing that with the exception of certain gamma-aminobutyric acid transporters, virtually all components of the glutamate-glutamine- gamma-aminobutyric acid cycle are, in some way or other, abnormal in suicide victims, which indicates a prominent involvement of the glutamatergic and gammaaminobutyric acidergic neurotransmitter systems in suicidal behaviour. In the second part we present own immunohistochemical findings showing that densities of glutamine synthetase expressing glial cells in the mediodorsal thalamus as well as in the dorsolateral prefrontal and orbitofrontal cortex of schizophrenic suicide completers are significantly elevated compared with controls and non-suicide individuals with schizophrenia, thus calling into question the belief that cerebral glutamine synthetase deficit is indicative of suicidal behaviour.
Export Options
About this article
Cite this article as:
Bernstein Hans-Gert, Tausch Anne, Wagner Rebecca, Steiner Johann, Seeleke Patrick, Walter Martin, Dobrowolny Henrik and Bogerts Bernhard, Disruption of Glutamate-Glutamine-GABA Cycle Significantly Impacts on Suicidal Behaviour: Survey of the Literature and Own Findings on Glutamine Synthetase., CNS & Neurological Disorders - Drug Targets 2013; 12 (7) . https://dx.doi.org/10.2174/18715273113129990091
DOI https://dx.doi.org/10.2174/18715273113129990091 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Febrile Infection-Related Epilepsy Syndrome (FIRES): An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Truly “Rational” Polytherapy: Maximizing Efficacy and Minimizing Drug Interactions, Drug Load, and Adverse Effects
Current Neuropharmacology High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry A Review on Repurposed Drugs and Vaccine Trials for Combating SARS CoV-2
Current Drug Research Reviews Meet the Editorial Board
CNS & Neurological Disorders - Drug Targets Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders
Current Signal Transduction Therapy A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia
Mini-Reviews in Medicinal Chemistry Mouse Models of Familial Hemiplegic Migraine for Studying Migraine Pathophysiology
Current Neuropharmacology Inquiries into the Biological Significance of Transmembrane AMPA Receptor Regulatory Protein (TARP) γ−8 Through Investigations of TARP γ−8 Null Mice§
CNS & Neurological Disorders - Drug Targets Targeted Nucleic Acid Delivery to Mitochondria
Current Gene Therapy Editorial [Is Suicidality Serious?]
Current Drug Safety Pathophysiology of Erectile Dysfunction
Current Drug Targets Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Animal Venom Peptides: Potential for New Antimicrobial Agents
Current Topics in Medicinal Chemistry 123I-FP-CIT Brain SPECT Findings in Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency
Current Radiopharmaceuticals Adenosine Dysfunction in Epilepsy and Associated Comorbidities
Current Drug Targets Update on Pharmacological Treatment of Progressive Myoclonus Epilepsies
Current Pharmaceutical Design